Navigation Links
A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease

A potential new experimental diagnostic test able to quickly distinguish individuals with active tuberculosis (TB) from those with latent TB infection has been developed. If the preliminary results of the study will be confirmed in a larger population sample, the new diagnostic system could allow more effective strategies to control the spread of the re-emerging pathology.

The work was performed by a group of scientists from the Catholic University of Rome, the National Institute of Infectious Diseases "L. Spallanzani" of Rome and the University of Sassari, in a study published on the international journal PLoS One.

TB is an infection caused by Mycobacterium tuberculosis, the bacterium known as Koch's bacillus, named after its discoverer (Robert Koch) in 1882. Following infection with the bacillus, two different scenario may occur: "active disease", clinically evident, and that - if not properly treated - can lead to death and the so called "latent infection", that is asymptomatic and that can last for a lifetime.

Worldwide it is estimated that no less than 2 billion people are infected with the TB bacillus in the latent form, and, luckily, only 5-10% of these infected individuals may develop TB disease. The causes responsible for the manifestation of the disease are still unknown and rapid diagnosis of patients with pulmonary TB is essential to reduce the cure time and to limit the spread of the infection to the community. Diagnosis of infection with Mycobacterium tuberculosis is still performed by the intradermal tuberculin test, developed in the early 20th century, used as a means of screening to determine the spread of infection in the population.

"The tuberculin skin test- explains Delia Goletti, corresponding author of the paper published on PLoS One and that together with Dr. Enrico Girardi has coordinated the study at the National Institute of Infectious Diseases 'L. Spallanzani' - has several drawbacks, primarily that is unable to differentiate between infection with environmental mycobacteria (typically not dangerous to humans), vaccination with Bacillus of Calmette et Guerin (BCG) and infection with M. tuberculosis. A new assay is being used since ten years, which includes a blood test, based on specific proteins of Mycobacterium tuberculosis. The new blood test, called "Interferon-γ release assays (IGRA)", based on the release of interferon-γ in response to M. tuberculosis-specific antigens, is able to selectively identify those who have contracted TB infection. "However continues Delia Goletti - IGRA, as well as the tuberculin test, are not able to distinguish people with latent TB infection compared to those with active TB disease ".

"The results of our study", says Giovanni Delogu, first author of the article, which, together with Prof. Giovanni Fadda has coordinated the research group at the Institute of Microbiology of the Catholic University of Rome - demonstrate that it is possible to distinguish those infected from those with the disease, by simply performing an extra blood test using a protein of the bacillus named HBHA".

"In order for the test to be effective, the HBHA protein must have special features, and to date it has been difficult to obtain large amounts of this protein. continues Delogu . Well, our research group has developed an innovative experimental protocol to obtain large amounts of protein with limited costs, opening the possibility to use this test on a large scale ".

"In this study we have developed an innovative diagnostic algorithm, which consists of a response to the protein HBHA in combination with the IGRA and the results have shown that the response to HBHA associates with latent TB infection. This procedure allows to rapidly identify those who really need the treatment for active TB ", concludes Delia Goletti.

"The response to HBHA can be used as a biomarkers for latent TB infection and then to some extent can be considered as a response of protection to TB. It is important to understand what are the mechanisms triggered by the infection which can cause the appearance or not of the disease", says Stefania Zanetti, professor of Microbiology at the University of Sassari.

"These results concludes the researchers open the road to a multicenter study -- "In the future we plan to extend the study to a larger number of patients, giving priority to certain groups where diagnosing active TB can be challenging, such as immunocompromised individuals and children. We also plan to tests the new assay in countries with a high burden of TB".

Contact: Giovanni Delogu - Delia Goletti
Catholic University of Rome

Related medicine news :

1. Extra Tests Not a Deterrent to Experimental Cancer Therapy
2. 2 Experimental Drugs Show Promise for Rare Pancreatic Cancer
3. Experimental approach may improve healing of diabetic wounds and bed sores
4. Study raises safety concerns about experimental cancer approach
5. First liver transplant patients receive experimental drug to prevent hepatitis C infection
6. Experimental Drug Helps Fight Aggressive Breast Cancer: Report
7. Experimental drug more potent, longer lasting than morphine
8. Experimental vaccine sets sights on lung cancer
9. Experimental Drug Raises Good Cholesterol Levels in Early Trial
10. UT Southwestern researchers create experimental vaccine against Alzheimers
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... ... 2015 , ... Holcomb – Kreithen Plastic Surgery and ... in Florida, is proud to announce that Dr. Joshua Kreithen, one of its ... a Johnson & Johnson Company. , Ethicon is a global medical device company ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support ... the programming and technical experience available within DataTrade to extend the services currently ...
(Date:11/30/2015)... ... 2015 , ... GKhair & Tibolli team members and artists were excited and ... November 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. ... top of the line fashion journalists. The San Juan Beauty Show carries immense credibility ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 --> ... "Dental Lasers Market by Product (Soft Tissue, All Tissue, Dental ... (Hospitals, Clinics), and Geography - Global Forecast to 2020", published ... 2020, at a CAGR of 5.2% during the forecast period ... data Tables and 62 Figures spread through 167 P ...
(Date:11/30/2015)... 2015  PTS Diagnostics, the U.S.-based manufacturer of point-of-care ... A1CNow ® systems, and PTS Detect™ cotinine systems, ... that will propel the company into the mHealth market. ... Europe . The technology is a system that ... smartphones and tablets, and uses test strip technology already ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: